• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Vision research advocates request NEI funding

Article

Washington, DC -- Members of the Alliance for Eye and Vision Research updated Congressional staffers about the latest developments in LASIK and corneal healing, and asked that Congress keep its promise to double the National Eye Institute's budget.

Related Videos
Related Content
Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Ocugen completes dosing of subjects with geographic atrophy in Cohort 2 of Phase 1/2 ArMaDa clinical trial of OCU410

Article
Ehsan Sadri, MD, leads an ophthalmology innovation discussion with Jeffry Weinhuff of Visionary Ventures

(EyePod) From idea to impact: Navigating ophthalmic innovation

Podcast
Intracortical Visual Prosthesis achieves 2 years of successful testing

Intracortical Visual Prosthesis achieves 2 years of successful testing

Article
EyePod: Modifier Gene Therapy: What is it?

EyePod: Modifier Gene Therapy: What is it?

Podcast
Using extracellular vesicles in the treatment of ocular diseases

Using extracellular vesicles in the treatment of ocular diseases

Article
Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Ocular Therapeutix announces positive topline Phase 1 data for Axpaxli in diabetic retinopathy

Article
© 2024 MJH Life Sciences

All rights reserved.